David Hollander
CIK 1793796 · CMO & Global Therapeutics Lead · last filed 2025-04-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
12
Lifetime Open-Market Net
-$16.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KPRX | Director | — | $2.55 | — | $0 | 5 | 2025-04-02 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CMO & Global Therapeutics Lead | 0 | $3.65 | $0 | -$16.3K | 2 | 2025-02-06 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | Chief R&D Officer | 30,749 | $15.25 | $468.9K | $0 | 5 | 2022-02-08 |
Recent Filings · Page 2 of 2
12 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-12 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Tax (F) | −2,162 | -$28.2K | EDGAR |
| 2019-11-13 | AERIE PHARMACEUTICALS INC (AERI) Delisted | Grant (A) | +25,000 | $0 | EDGAR |
Showing 11–12 of 12
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.